Caring for the older person with chronic obstructive pulmonary disease

JAMA

Volumn 308, Issue 12, 2012, Pages 1254-1263

  Fried, Terri R ^a,b   Vaz Fragoso, Carlos A ^a,b   Rabow, Michael W ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZITHROMYCIN; BUSPIRONE; CARBOXYMETHYLCELLULOSE; CEFTRIAXONE; COLECALCIFEROL; DORZOLAMIDE; FORMOTEROL; IPRATROPIUM BROMIDE; LEVOFLOXACIN; LISINOPRIL; METFORMIN; METHYLPREDNISOLONE; MIRTAZAPINE; MOMETASONE FUROATE; OMEPRAZOLE; OXYCODONE PLUS PARACETAMOL; OXYGEN; PREDNISONE; SALBUTAMOL; SERTRALINE; SIMVASTATIN; TIOTROPIUM BROMIDE; TRAVOPROST; TRIAZOLAM;

AGED; BEDTIME DOSAGE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON DIVERTICULOSIS; CORONARY ARTERY DISEASE; DAILY LIFE ACTIVITY; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DYSPNEA; ELDERLY CARE; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; GLAUCOMA; HEART FAILURE; HOME OXYGEN THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTENSIVE CARE UNIT; MALE; NECK INJURY; POSITIVE END EXPIRATORY PRESSURE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; TACHYCARDIA; WHEEZING;

EID: 84866560630     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.12422     Document Type: Review

References (104)

1. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012;156(10):673-683.
2. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. http://www.goldcopd.org/. 2011. Accessed June 29, 2012.
3. Standards for the Diagnosis and Management of Patients With COPD. American Thoracic Society/European Respiratory Society website. http://www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf. 2004. Accessed June 29, 2012.
4. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
5. Fragoso CAV, Concato J, McAvay G, Yaggi HK, Van Ness PH, Gill TM. Staging the severity of chronic obstructive pulmonary disease in older persons based on spirometric Z-scores. J Am Geriatr Soc. 2011;59(10):1847-1854.
6. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300(20):2417-2419.
7. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136(2):376-380.
8. Morrison NJ, Richardson J, Dunn L, Pardy RL. Respiratory muscle performance in normal elderly subjects and patients with COPD. Chest. 1989;95(1):90-94.
9. Chatham K, Gelder CM, Lines TA, Cahalin LP. Suspected statin-induced respiratory muscle myopathy during long-term inspiratory muscle training in a patient with diaphragmatic paralysis. Phys Ther. 2009;89(3):257-266.
10. Chan ED, Welsh CH. Geriatric respiratory medicine. Chest. 1998;114(6):1704-1733.
11. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res. 2007;22(3):447-457.
12. Vaz Fragoso CA, Gill TM. Respiratory impairment and the aging lung: a novel paradigm for assessing pulmonary function. J Gerontol A Biol Sci Med Sci. 2012;67(3):264-275.
13. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211-277.
14. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(13):1329-1335.
15. American Thoracic Society. Dyspnea: mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159(1):321-340.
16. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007;131(5)(suppl):4S-42S.
17. ZuWallack R, Hedges H. Primary care of the patient with chronic obstructive pulmonary disease - part 3: pulmonary rehabilitation and comprehensive care for the patient with chronic obstructive pulmonary disease. Am J Med. 2008;121(7)(suppl):S25-S32.
18. O'Donnell DE. Breathlessness in patients with chronic airflow limitation: mechanisms and management. Chest. 1994;106(3):904-912.
19. Karapolat H, Eyigor S, Atasever A, Zoghi M, Nalbantgil S, Durmaz B. Effect of dyspnea and clinical variables on the quality of life and functional capacity in patients with chronic obstructive pulmonary disease and congestive heart failure. Chin Med J (Engl). 2008;121(7):592-596.
20. Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here? Am J Respir Crit Care Med. 1997;156(4, pt 1):1032-1039.
21. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016.
22. Alonso-Coello P, Bellmunt S, McGorrian C, et al; American College of Chest Physicians. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e669S-e690S.
23. Ioannidis JPA. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169(19):1737-1739.
24. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ. 2006;174(5):645-646.
25. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
26. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359 (15):1543-1554.
27. Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease." Arch Intern Med. 2011;171(10):920-922.
28. Hordijk-Trion M, Lenzen M, Wijns W, et al; EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27(6):671-678.
29. Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med. 2011;171(10):914-920.
30. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123(6):1964-1969.
31. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58-69.
32. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? a comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55(12):1000-1006.
33. Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. J Palliat Med. 2010;13(9):1109-1118.
34. Claessens MT, Lynn J, Zhong Z, et al; Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. J Am Geriatr Soc. 2000;48(5)(suppl):S146-S153.
35. Lanken PN, Terry PB, Delisser HM, et al; ATS End-of-Life Care Task Force. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912-927.
36. Clemens KE, Faust M, Bruera E. Update on combined modalities for the management of breathlessness. Curr Opin Support Palliat Care. 2012;6(2):163-167.
37. Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness: a future work plan? J Pain Symptom Manage. 2012;43(3):614-624.
38. Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP. Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med. 2012;15(1):106-114.
39. Rocker G, Young J, Donahue M, Farquhar M, Simpson C. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ. 2012;184(9):E497-E504.
40. Katsura H, Kanemaru A, Yamada K, Motegi T, Wakabayashi R, Kida K. Long-term effectiveness of an inpatient pulmonary rehabilitation program for elderly COPD patients: comparison between young-elderly and old-elderly groups. Respirology. 2004;9(2):230-236.
41. Baltzan MA, Kamel H, Alter A, Rotaple M, Wolkove N. Pulmonary rehabilitation improves functional capacity in patients 80 years of age or older. Can Respir J. 2004;11(6):407-413.
42. Di Meo F, Pedone C, Lubich S, Pizzoli C, Traballesi M, Incalzi RA. Age does not hamper the response to pulmonary rehabilitation of COPD patients. Age Ageing. 2008;37(5):530-535.
43. Williams SJ, Bury MR. Impairment, disability and handicap in chronic respiratory illness. Soc Sci Med. 1989;29(5):609-616.
44. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691-1699.
45. Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med. 2008;121(9):789-796.
46. Thakur N, Blanc PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis. 2010;5:263-269.
47. Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med. 1992;93(6):663-669.
48. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA. 1998;279(15):1187-1193.
49. Bharucha AJ, Pandav R, Shen C, Dodge HH, Ganguli M. Predictors of nursing facility admission: a 12-year epidemiological study in the United States. J Am Geriatr Soc. 2004;52(3):434-439.
50. Allen SC. Competence thresholds for the use of inhalers in people with dementia. Age Ageing. 1997;26(2):83-86.
51. Allen SC, Jain M, Ragab S, Malik N. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing. 2003;32(3):299-302.
52. Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209-218.
53. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T, Brooks D. Impairments in balance discriminate fallers from non-fallers in COPD. Respir Med. 2009;103(12):1885-1891.
54. Roig M, Eng JJ, Road JD, Reid WD. Falls in patients with chronic obstructive pulmonary disease: a call for further research. Respir Med. 2009;103(9):1257-1269.
55. Reuben DB, Rosen S. Principles of geriatric assessment. In: Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S, eds. Hazzard's Geriatric Medicine and Gerontology. 6th ed. New York, NY: McGraw-Hill; 2009.
56. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The Mini-Cog: a cognitive "vital signs" measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021-1027.
57. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35(4):913-922.
58. Heaton RK, Grant I, McSweeny AJ, Adams KM, Petty TL. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med. 1983;143(10):1941-1947.
59. Emery CF, Green MR, Suh S. Neuropsychiatric function in chronic lung disease: the role of pulmonary rehabilitation. Respir Care. 2008;53(9):1208- 1216.
60. Spitzer RL, Williams JBW, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA. 1994;272(22):1749-1756.
61. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205-1211.
62. Kunik ME, Azzam PN, Souchek J, et al. A practical screening tool for anxiety and depression in patients with chronic breathing disorders. Psychosomatics. 2007;48(1):16-21.
63. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33(2):190-201.
64. Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. Psychol Med. 2008;38(3):385-396.
65. Howard C, Dupont S, Haselden B, Lynch J, Wills P. The effectiveness of a group cognitive-behavioural breathlessness intervention on health status, mood and hospital admissions in elderly patients with chronic obstructive pulmonary disease. Psychol Health Med. 2010;15(4):371-385.
66. Maurer J, Rebbapragada V, Borson S, et al; ACCP Workshop Panel on Anxiety and Depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4)(suppl):43S-56S.
67. Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest. 2011;139(3):648-657.
68. Tinetti ME. Clinical practice: preventing falls in elderly persons. N Engl J Med. 2003;348(1):42-49.
69. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269-2276.
70. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716-724.
71. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
72. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349-1354.
73. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and weight loss or impaired balance in older adults. J Am Geriatr Soc. 2004;52(10):1719-1723.
74. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med. 2011;171(20):1854-1856.
75. Connors AF Jr, Dawson NV, Thomas C, et al; SUPPORT Investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Outcomes following acute exacerbation of severe chronic obstructive lung disease [published correction appears in Am J Respir Crit Care Med. 1997;155(1):386]. Am J Respir Crit Care Med. 1996;154:959-967.
76. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796-803.
77. Fried TR, Bradley EH, O'Leary J. Prognosis communication in serious illness: perceptions of older patients, caregivers, and clinicians. J Am Geriatr Soc. 2003;51(10):1398-1403.
78. Quill TE. Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: addressing the "elephant in the room." JAMA. 2000; 284(19):2502-2507.
79. Tulsky JA. Beyond advance directives: importance of communication skills at the end of life. JAMA. 2005;294(3):359-365.
80. Back AL, Arnold RM. Discussing prognosis: "how much do you want to know?": talking to patients who are prepared for explicit information. J Clin Oncol. 2006;24(25):4209-4213.
81. Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. Ann Intern Med. 2010;153(4):256-261.
82. Quill TE, Holloway R. Time-limited trials near the end of life. JAMA. 2011;306(13):1483-1484.
83. Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061-1066.
84. Pinnock H, Kendall M, Murray SA, et al. Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ. 2011;342:d142.
85. White P, White S, Edmonds P, et al. Palliative care or end-of-life care in advanced chronic obstructive pulmonary disease: a prospective community survey. Br J Gen Pract. 2011;61(587):e362-e370.
86. Mahler DA. Understanding mechanisms and documenting plausibility of palliative interventions for dyspnea. Curr Opin Support Palliat Care. 2011;5(2):71-76.
87. Varkey B. Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2010;16(2):150-154.
88. Luce JM, Luce JA. Management of dyspnea in patients with far-advanced lung disease: "Once I lose it, it's kind of hard to catch it . . . ". JAMA. 2001;285:1331-1337.
89. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42(3):388-399.
90. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2010;(1):CD007354.
91. Marciniuk DD, Goodridge D, Hernandez P, et al; Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69-78.
92. Horton R, Rocker G. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Curr Opin Support Palliat Care. 2010;4(2):56-62.
93. Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007;52(7):900-910.
94. Abernethy AP, Uronis HE, Wheeler JL, Currow DC. Management of dyspnea in patients with chronic obstructive pulmonary disease. Wien Med Wochenschr. 2009;159(23-24):583-590.
95. Hunt T, Williams MT, Frith P, Schembri D. Heliox, dyspnoea and exercise in COPD. Eur Respir Rev. 2010;19(115):30-38.
96. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a doubleblind, randomised controlled trial. Lancet. 2010;376(9743):784-793.
97. Rafii R, Albertson TE, Louie S, Chan AL. Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease [published online April 20, 2011]. Pulm Med. 2011;2011:257496. doi:10.1155/2011/257496.
98. Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348 (21):2059-2073.
99. Berger RL, Decamp MM, Criner GJ, Celli BR. Lung volume reduction therapies for advanced emphysema: an update. Chest. 2010;138(2):407-417.
100. Elliott MW. Non-invasive ventilation: established and expanding roles. Clin Med. 2011;11(2):150-153.
101. Smith TA, Davidson PM, Lam LT, Jenkins CR, Ingham JM. The use of noninvasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease: a systematic review. Respirology. 2012;17(2):300-307.
102. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis. 1987;136(1):58-61.
103. Suzuki M, Muro S, Ando Y, et al. A randomized, placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD): the COPD-acupuncture trial (CAT). Arch Intern Med. 2012;172(11):878-886.
104. Clini EM, Ambrosino N. Nonpharmacological treatment and relief of symptoms in COPD. Eur Respir J. 2008;32(1):218-228.